Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort
View/ Open
Author
Hou, Lifang
Joyce, Brian Thomas
Gao, Tao
Liu, Lei
Zheng, Yinan
Penedo, Frank J.
Liu, Siran
Zhang, Wei
Bergan, Raymond
Dai, Qi
Vokonas, Pantel
Hoxha, Mirjam
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1016/j.ebiom.2015.04.008Metadata
Show full item recordCitation
Hou, L., B. T. Joyce, T. Gao, L. Liu, Y. Zheng, F. J. Penedo, S. Liu, et al. 2015. “Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort.” EBioMedicine 2 (6): 591-596. doi:10.1016/j.ebiom.2015.04.008. http://dx.doi.org/10.1016/j.ebiom.2015.04.008.Abstract
Background: Accelerated telomere shortening may cause cancer via chromosomal instability, making it a potentially useful biomarker. However, publications on blood telomere length (BTL) and cancer are inconsistent. We prospectively examined BTL measures over time and cancer incidence. Methods: We included 792 Normative Aging Study participants with 1–4 BTL measurements from 1999 to 2012. We used linear mixed-effects models to examine BTL attrition by cancer status (relative to increasing age and decreasing years pre-diagnosis), Cox models for time-dependent associations, and logistic regression for cancer incidence stratified by years between BTL measurement and diagnosis. Findings: Age-related BTL attrition was faster in cancer cases pre-diagnosis than in cancer-free participants (pdifference = 0.017); all participants had similar age-adjusted BTL 8–14 years pre-diagnosis, followed by decelerated attrition in cancer cases resulting in longer BTL three (p = 0.003) and four (p = 0.012) years pre-diagnosis. Longer time-dependent BTL was associated with prostate cancer (HR = 1.79, p = 0.03), and longer BTL measured ≤ 4 years pre-diagnosis with any (OR = 3.27, p < 0.001) and prostate cancers (OR = 6.87, p < 0.001). Interpretation Age-related BTL attrition was faster in cancer cases but their age-adjusted BTL attrition began decelerating as diagnosis approached. This may explain prior inconsistencies and help develop BTL as a cancer detection biomarker.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535161/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:21459141
Collections
- HMS Scholarly Articles [17917]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)